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Murine ES cells (129 CCE) obtained from Dr. Nagy laboratory,
Canada, were subjected to the in vitro primary hematopoietic
differentiation media containing methylcellulose, IMDM, IL -3,
IL-6, and SCF (stem cell factor) without LIF (leukemia inhibitory
factor) to promote embryoid body (EB) formation. Total RNA was
collected on day 3, 5, and 9 EBs for gene expression studies using
RT-PCR. On day 9, EBs were subjected to secondary differenti-
ation using three different cytokines and growth factors combina-
tion, (1) SCF, EPO, dexamethasone, IGF, (2) SCF, IL-3, IL-6,
TPO, (3) SCF IL-3, IL-6, TPO, EPO. Total RNA from day12 of
secondary differentiated ES cells was collected to study cytokines
and growth factors dependent erythrocytic differentiation and gene
regulation, using RT-PCR. Our results demonstrate upregulation
of Gata-1, Flk-1, HoxB-4, Epo-R, and globin genes (
-globin,
BH-1 globin, b-major globin, e-globin, and z-globin) in the 9 days
old EBs, whereas RNA collected from 5 days old EBs showed
expression of HoxB-4, e-globin, -globin, BH1-globin, and
FLK-1. Three days old EBs showed only HoxB-4 and FLK-1 gene
expression and lack of expression of globin genes, indicating that
erythropoiesis-speciﬁc genes and hemoglobin switch activate later.
Gene expression studies of RNA collected from secondary differ-
entiated ES cells and media containing dexamethasone showed
downregulation of GATA-3 and upregulation of GATA-1, Flk-1,
and Epo-R in comparison to the two other cytokines and growth
factors media combination. These results conﬁrm our hypothesis
that dexamethasome induces erythropoiesis by downregulating
GATA 3 and upregulating erythropoietic genes such as
GATA-1, Flk-1, and Epo-R. The morphological characteristics of
cells after secondary differentiation showed enhanced production
of erythrocytic precursors in dexamethasone containing media,
which corresponded with molecular studies.
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SHORT TERM AND PROLONGED EFFECTS OF IRRADIATION ON HUMAN
MESENCHYMAL STEM CELLS
Li, J.1, Kwong, D.L.W.2, Chan, G.C.F.1 1. Department of Paediatrics
& Adolescent Medicine, The University of Hong Kong, HKSAR, China;
2. Department of Clinical Oncology, The University of Hong Kong,
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Background: Mesenchymal stem cells (MSCs) are important com-
ponent of the bone marrow microenvironment and are progenitors of
mesenchymal tissues. The effect of therapeutic irradiation to MSCs
remains unexplored. Materials and Methods: MSCs were derived
from healthy donors. Effects of irradiation with single dose (dosage
ranges 2, 4, 6, 8, 12 Gy) on human MSCs were investigated. Post-
irradiation cell proliferation was assessed by XTT assay and cell
counting. Osteogenic and adipogenic differentiation function were
evaluated after irradiation. ALP activity and calcium deposition in
irradiated MSCs were quantiﬁed following osteogenic induction. Re-
sults: Irradiation inhibited proliferation of human MSCs up to 2
weeks post-irradiation but thereafter, survival cells regained normal
proliferation rate back to the control level. ALP activity and calcium
deposition were both reduced in a dose-dependant fashion. Maximum
reduction (16% of control ALP activity and 9% of control calcium
level) was noted in MSCs under 12 Gy irradiation. Adipocyte per-
centage was reduced by 50% in cultures that received irradiation 	4
Gy. Attempts to protect the irradiated cells with 1 M all-trans
retinoic acid showed no protective effect on MSCs proliferation and
differentiation. Conclusion: Irradiation damaged the capacity of hu-
man MSCs proliferation and differentiation. However, full recovery
of growth and renewal ability was observed in surviving MSCs after 2
weeks.
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CORD BLOOD EXPANSION WITH SELECTIVE DEPLETION OF CD52
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The overgrowth of mature haematopoietic cells leads to a reduc-
tion of the long term proliferative potential of cord blood expan-
sion cultures. We postulated that the depletion of CD52 positive
cells in these cultures could lead to a higher percentage of imma-
ture progenitors including CD34 positive cells and megakaryocyte
progenitors. Immunomagnetic isolation of CD34 cells was per-
formed on leukocyte enriched cord blood samples, followed by
culture in SFEM serum free medium in the presence of 50 mg/ml
of: stem cell factor (SCF); Flt3-ligand and thrombopoietin (Tpo)
for up to 14 days. Well-demarcated populations of CD52 and
CD34 positive cells were found on ﬂow cytometric analysis. Phar-
maceutical-grade humanized anti-CD52 monoclonal antibody
Campath-1H was used, in the presence of complement, to deplete
CD52 positive cells during the cord blood expansion cultures.
Addition of the antibody resulted in a signiﬁcant reduction of
CD52 positive cells in the cord blood cultures versus cells grown in
culture without anti-CD52 antibodies (CD52 cells 0.64% with
Campath-1H versus 13.76% in cultures without the antibody
added). The percentage of CD34 positive cells (7.13% with Cam-
path-1H versus 1.04% in cultures without antibody) and
megakaryocyte progenitors after 3 weeks of cultures were also
higher in Campath-1H treated cord blood cultures. The differ-
ences were more pronounced when Interleukin-3 (IL3) was added
to the cytokine cocktail for cord blood expansion. We conclude
that anti-CD52 antibodies may be used to deplete mature cells
from cord blood cultures resulting in a signiﬁcantly higher per-
centage of immature CD34 positive cells and megakaryocytic pro-
genitors.
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CELL TRANSPLANT SURVIVORS
Nivison-Smith, I.1, Bradstock, K.F.2, Dodds, A.J.3, Ma, D.D.F.3,
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Aim: To measure mortality rates in long-term hemopoietic stem
cell transplant survivors and compare these with the general pop-
ulation. Method: Records of patients who had survived more than
2 years post autologous or allogeneic stem cell transplant were
drawn from the ABMTRR database. Annual mortality was calcu-
lated for this group and compared to the mortality of the Australian
population using indirect age-standardized mortality rates. Re-
sults: Among 1502 allogeneic recipients disease free at 2 years,
there were 36 deaths (18 from non-malignancy related causes) in
the third year compared to an expected 3. Among 778 allogeneic
recipients disease free at 5 years, there were 3 deaths in the sixth
year deaths (2 from non-malignancy related causes) compared to
an expected 1. In contrast, among 2741 autologous recipients
disease free at 2 years, there were 52 deaths (8 from non-malig-
nancy related causes) in the third year compared to an expected 9.
Among 1188 autologous recipients disease free at 5 years, there
were 14 deaths in the sixth year (6 non-malignancy) compared to
an expected 3.Conclusion:The non-malignancy mortality of both
allogeneic and autologous HSCT recipients approaches population
norms for those who survive more than 5 years post transplant.
Indirect age-standardized mortality calculations offer a relatively
straightforward mortality analysis strategy. The ABMTRR is an
important national data resource providing timely information on
transplant activity and outcome across Australia and New Zealand.
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